{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:49:33Z","timestamp":1782827373191,"version":"3.54.5"},"reference-count":14,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT Background Variceal hemorrhage (VH) is a medical emergency. Prompt endoscopic variceal ligation (EVL) is therapeutic. Terlipressin is used in VH and continued for 2\u20145 days even after EVL. As hemostasis is primarily achieved by EVL, the benefit of continuing trelipressin after EVL is unknown. Objective To evaluate the efficacy of continuing terlipressin after EVL to prevent re-bleed and mortality. Methods In this pilot study, after EVL 74 patients of VH were randomized into two treatment groups TG2 &amp; TG5, received terlipressin (1 mg IV bolus q 4 hourly) for 2 days and 5 days respectively and one control group (TG0), received 0.9% normal saline (10 mL IV bolus q 4 hourly) and followed up for 8 weeks. Results A total of 9 (12.6%) patients had re-bleed with maximum 4 (5.6%) patients in TG5 group followed by 3 (4.2%) in TG2 and 2 (2.8%) in TG0 groups (P=0.670). The overall mortality was 15 (21.1%) patients, 6 (8.5%) patients in TG0 group, followed by 5 (7.0%) in TG5 and 4 (5.6%) in TG2 group (P=0.691). Adverse drug reactions were significantly higher in treatment groups with maximum 18 (24.32%) patients in TG5, followed by 8 (10.8%) in TG2 and 2 (2.7%) in TG0 groups (P=0.00). Duration of hospital stay was also significantly higher in treatment group, 6.63 (\u00b10.65) days in TG5 followed by 3.64 (\u00b10.57) in TG2 and 2.40 (\u00b10.50) days in TG0 groups (P=0.00). Conclusion The rational for continuing terlipressin after EVL is doubtful as it didn\u2019t have any benefit for the prevention of re-bleed or mortality; rather it increased the risk of adverse drug reactions and duration of hospital stay. Further randomized clinical trials are encouraged to generate more evidence in support or against continuing terlipressin after EVL.<\/jats:p>","DOI":"10.1590\/s0004-2803.202200001-16","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T19:02:11Z","timestamp":1650049331000},"page":"89-96","source":"Crossref","is-referenced-by-count":7,"title":["RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY"],"prefix":"10.1590","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-5558","authenticated-orcid":false,"given":"Ram Chandra","family":"POUDEL","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-0160","authenticated-orcid":false,"given":"Deba Prasad","family":"DHIBAR","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-3409","authenticated-orcid":false,"given":"Navneet","family":"SHARMA","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5707-9686","authenticated-orcid":false,"given":"Vishal","family":"SHARMA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-6969","authenticated-orcid":false,"given":"Sunil","family":"TANEJA","sequence":"additional","affiliation":[{"name":"Department of Hepatology, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3487-8482","authenticated-orcid":false,"given":"Ajay","family":"PRAKASH","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis and management: 2016 practice guidance by the American Association for the Study of Liver Diseases","volume":"65","author":"Garcia-Tsao G","year":"2017","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s12325-008-0118-7","article-title":"Efficacy and Safety of Terlipressin in Cirrhotic Patients with Variceal Bleeding or Hepatorenal Syndrome","volume":"25","author":"Krag A","year":"2008","journal-title":"Adv Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/hep.23893","article-title":"Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension","volume":"52","author":"Sola E","year":"2010","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.dld.2007.11.009","article-title":"Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome","volume":"40","author":"Di Micoli A","year":"2008","journal-title":"Dig Liver Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7869\/tg.373","article-title":"Utility of clinical and complete Rockall score in Indian patients with upper gastrointestinal bleeding","volume":"37","author":"Sharma V","year":"2016","journal-title":"Trop Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients","volume":"39","author":"D\u2019Amico G","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","first-page":"743","article-title":"Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis R","year":"2015","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding","volume":"368","author":"Villanueva C","year":"2013","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gut.2007.137489","article-title":"Predictors of rebleeding and mortality following acute variceal hemorrhage in patients with cirrhosis","volume":"57","author":"Bambha K","year":"2008","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004836-198902000-00014","article-title":"Placebo-Controlled Trial of Terlipressin (Glypressin) in the management of acute variceal bleed","volume":"11","author":"Freeman JG","year":"1989","journal-title":"J Clin Gastroenterol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3109\/00365529009095539","article-title":"Terlipressin (Triglycyl-Lysine Vasopressin) Controls Acute Bleeding Oesophageal Varices: A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"6","author":"S\u00f6derlund C","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"ref12","first-page":"613","article-title":"Terlipressin in combination with endoscopic variceal ligation for prevention of acute esophageal variceal rebleeding","volume":"18","author":"Peng Y","year":"2013","journal-title":"Indian J Gastroenterol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0011-393X(05)80451-5","article-title":"Randomized controlled trial with Terlipressin in cirrhotic patients with bleeding esophageal varices: Effects on precocious rebleeding and mortality rate","volume":"52","author":"Arcidiacono R","year":"1992","journal-title":"Current Therapeautic Research"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013437","article-title":"Terlipressin for the treatment of acute variceal bleeding. A systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Zhou X","year":"2018","journal-title":"Medicine"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["O uso cont\u00ednuo da terlipressina ap\u00f3s a ligadura endosc\u00f3pica em hemorragia varicosa aguda necessita de mais evid\u00eancias: um estudo piloto"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032022000100089&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:24:49Z","timestamp":1675319089000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032022000100089&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["S0004-28032022000100089"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202200001-16","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}